Ireland🏛️ PoliticsProgressiveOverlooked by conservatives8/23/2026
Campaigners in final push for Skyclarys approval
Campaigners in Ireland are making their final effort to secure approval for the drug Skyclarys, which treats Friedreich's Ataxia, a rare and progressive neuromuscular disorder affecting approximately 200 individuals in the country. A demonstration took place in Dublin, with advocates and patients gathering at the Garden of Remembrance and marching to Custom House Quay to urge the Health Service Executive (HSE) to reimburse the medication. Earlier this month, the HSE Drugs Group advised against covering the drug’s costs, citing concerns raised by the National Centre for Pharmacoeconomics regarding the limited and uncertain clinical data supporting its efficacy. Despite these recommendations, there is significant support for the drug's approval from both opposition parties and members of Fianna Fáil and Fine Gael. The final decision will be made by the HSE during a senior management meeting on Tuesday. The drug, approved by the European Medicines Agency in 2024, could cost up to €280,000 per patient annually, leading to a potential five-year budget impact of €130 million.
Campaigners in Ireland have launched a final push for the approval of Skyclarys, a drug used to treat Friedreich’s ataxia, after the HSE Drugs Group recommended against covering its costs. The campaign, led by patients and advocacy groups, has culminated in a public demonstration in Dublin city centre, with participants gathering at the Garden of Remembrance before marching to Custom House Quay. The protest marks the latest stage in a long-running effort to secure reimbursement for the medication, which has been shown to slow the progression of the rare, degenerative neurological disorder. Friedreich’s ataxia is a progressive neuromuscular condition that leads to nerve damage, muscle weakness, and eventual loss of mobility. It affects approximately 200 individuals in Ireland, according to estimates. The disease typically manifests in childhood or adolescence and gradually worsens over time, often leading to severe disability. Patients describe the condition as relentless, with symptoms worsening steadily unless intervention occurs early. The phrase “Friedreich’s ataxia won’t stop until every aspect of your life is ruined” has become a rallying cry among sufferers, encapsulating their frustration with the lack of effective treatment options. Skyclarys, developed by Sanofi, was first approved by the European Medicines Agency in 2024. Its potential to slow disease progression has made it a critical option for many affected families. However, the high cost of the drug, approximately €280,000 per patient per year, has raised concerns about affordability and sustainability. Over a five-year period, the total financial impact could reach nearly €130 million, prompting scrutiny from health authorities. The HSE’s Drugs Group evaluated the drug’s effectiveness and concluded that while there is some evidence of slowed progression, the available clinical data remains limited and uncertain. In response, the HSE initiated a review process over two years ago, during which the National Centre for Pharmacoeconomics conducted an assessment. This evaluation highlighted both the therapeutic benefits and the economic challenges posed by Skyclarys. Despite these findings, supporters argue that the drug offers a lifeline to those living with the condition, particularly given the absence of alternative treatments. Campaigners have emphasized that delaying access to Skyclarys risks further deterioration of quality of life for patients. Political backing for the campaign has grown significantly, with support emerging from multiple political parties. Opposition parties, including Fianna Fáil and Fine Gael, have expressed solidarity with the cause, urging the HSE to reconsider its stance. A recent letter from Fianna Fáil challenged the HSE’s position, highlighting the ethical implications of denying access to potentially life-changing care. Advocacy groups have also mobilized public support, emphasizing the need for equitable healthcare access for rare diseases. The final decision rests with the HSE, which will convene a senior management meeting on Tuesday to determine whether to approve reimbursement for Skyclarys. The outcome of this meeting will have profound implications for patients and their families, who continue to advocate for timely and accessible treatment. As the deadline approaches, the pressure mounts on policymakers to balance fiscal responsibility with the urgent medical needs of those affected by Friedreich’s ataxia. The coming days will reveal whether the voices of the afflicted will be heard.
3 reports
The Irish TimesIndependent🔒ProgressiveFactual 85Objective 788/23/2026
Isabella Travers, a 19-year-old from Co Wicklow, was diagnosed with Friedreich’s ataxia (FA) at age 12. The progressive neurological disorder has led to her becoming a full-time wheelchair user. She and others with FA are awaiting a decision from Ireland’s Health Service Executive (HSE) regarding the reimbursement of Skyclarys, a drug approved in the EU for slowing the disease’s progression. Despite EU approval, the drug remains unaffordable in Ireland due to a cost-effectiveness assessment deeming it too expensive. The HSE has twice rejected reimbursement requests, citing costs around €280,000 per patient annually. Advocates argue the price reflects list prices rather than negotiated rates and emphasize the life-changing potential of the medication. A protest is planned in Dublin to demand access to the drug.
Bias read (Progressive): The article frames the issue as a moral and ethical dilemma, emphasizing the human impact of the HSE’s decision and portraying the pharmaceutical pricing as unjust. While it presents both sides (HSE cost concerns vs. patient advocacy), the tone leans toward highlighting the hardship faced by those罹患
Why factuality (85): The article provides detailed information about Friedreich’s ataxia, the drug Skyclarys, and the current status of its reimbursement in Ireland. It cites specific dates, numbers, and official decisions from the HSE and the National Centre for Pharmacoeconomics. While there is no primary source docum
Why objectivity (78): The tone is empathetic and highlights the personal impact of the decision on patients like Isabella Travers. While this is appropriate given the subject matter, it leans slightly towards advocacy for the patients' cause, which may introduce a degree of bias. The article does not present opposing vie
Campaigners in Ireland are making their final effort to secure approval for the drug Skyclarys, which treats Friedreich's Ataxia, a rare and progressive neuromuscular disorder affecting approximately 200 individuals in the country. A demonstration took place in Dublin, with advocates and patients gathering at the Garden of Remembrance and marching to Custom House Quay to urge the Health Service Executive (HSE) to reimburse the medication. Earlier this month, the HSE Drugs Group advised against covering the drug’s costs, citing concerns raised by the National Centre for Pharmacoeconomics regarding the limited and uncertain clinical data supporting its efficacy. Despite these recommendations, there is significant support for the drug's approval from both opposition parties and members of Fianna Fáil and Fine Gael. The final decision will be made by the HSE during a senior management meeting on Tuesday. The drug, approved by the European Medicines Agency in 2024, could cost up to €280,000 per patient annually, leading to a potential five-year budget impact of €130 million.
Bias read (Progressive): The article frames the issue as a moral and health-related imperative, emphasizing the suffering of patients and the need for access to treatment. It highlights the support from multiple political parties and portrays the HSE's recommendation as a barrier to necessary care. While it presents both H4
Why factuality (78): The article provides factual information about the campaign for Skyclarys approval, including details about the condition, the demonstration, and the HSE's previous recommendation. It cites the European Medicines Agency's 2024 approval and mentions the estimated cost and budget impact. However, it l
Why objectivity (82): The article presents the situation in a neutral tone, reporting both sides of the issue, campaigners' demands and the HSE's concerns. It avoids emotionally charged language and focuses on facts rather than taking a clear editorial position. The mention of political support adds context but remains o
The article highlights the experiences of individuals living with Friedreich’s ataxia, a rare neurological disorder that progressively impairs motor function and leads to severe disability. Patients describe the relentless nature of the disease, which continues to deteriorate their quality of life despite medical interventions. The piece focuses on advocacy efforts by patients and families to gain access to potentially life-changing treatments, emphasizing the urgent need for new therapies. It underscores the personal toll of the condition and calls attention to the challenges faced by those affected, while also highlighting the broader implications for healthcare policy and research funding.
Bias read (Progressive): The article frames the struggle of Friedreich’s ataxia patients as a moral imperative, emphasizing the human cost of delayed treatment and the systemic failures in healthcare access. While not explicitly political, the narrative aligns with progressive values by advocating for increased investment,
Why factuality (75): The article reports on a campaign by people with Friedreich’s ataxia seeking life-changing medicine. While no primary source document was available, the content aligns with known information about the condition and advocacy efforts. The phrasing 'won’t stop until every aspect of your life is ruined'
Why objectivity (60): The article uses emotionally charged language such as 'won’t stop until every aspect of your life is ruined,' which may reflect the perspective of the campaigners rather than an objective description of the disease's impact. The tone leans toward empathy for the patients but does not present alterna
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.
Ireland
